PROGRAMS - Overview

Today more than 60 million American adults are suffering from mental illness. Despite the significant unmet medical need for drugs with improved efficacy and reduced side effects, the current pipeline of new agents is very limited. Furthermore, in the last 40 years, few new targets or breakthrough therapeutic approaches for treating psychiatric disorders have been identified.

Galenea aims to change the way central nervous system diseases are treated.

We take a mechanistic approach and have established improved predictive tools and behavioral models that will help drive our drug discovery programs. We believe that understanding neuronal function and network activity is critical for elucidating new mechanisms in CNS disease and for evaluating novel therapeutic agents. We have developed and employ novel in vitro and in vivo synaptic functional screening and brain slice electrophysiology assays. These include techniques for recording disease-relevant neuronal activity in the prefrontal cortex to precisely measure the effects of potential drug candidates in animals performing critical memory or cognition-dependent tasks. We are using these high-powered analytical methods to identify new mechanism-based treatments for CNS diseases.